Pfizer Inc.’s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the company sharing aims to start a pivotal programme in 2025.

A total of 187 patients underwent randomization. Of these patients, 40% had non–small-cell lung cancer, 32% had pancreatic cancer, and 29% had colorectal cancer. At 12 weeks, patients in the ...

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer cells, which is called cachexia, Pfizer said in a news release Saturday.

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer cells, which is called cachexia, Pfizer said in a news release Saturday.

Read this article to learn about supporting palliative care patients and their families with eating and drinking concerns.

This effect of histamine and methacholine was significantly reduced by propranolol. The terminal infusion of isoproterenol produced mean pulse acceleration of 10.4 per cent, 14.7 per cent and 10.2 ...

Credit: Jonathan Weiss / Shutterstock. Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the company sharing aims to start a ...

600010.SS Inner Mongolia Baotou Steel Union Co., Ltd.

Clinical and Radiographic Outcomes of Four Different Treatment Strategies in Patients With Early Rheumatoid Arthritis (the Best Study): A Randomized, Controlled Trialfrom Arthritis & Rheumatism ...